Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Kohek, PH; Pakisch, B; Glanzer, H; Höss, G; Mischinger, HJ; Wolf, G; Steindorfer, P.
Results of irradiation treatment in patients with non-resectable oesophageal cancer.
Eur J Surg Oncol. 1995; 21(6):627-631
Doi: 10.1016/S0748-7983(95)95391-4
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Mischinger Hans-Jörg
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Forty-eight patients with non-resectable cancer of the oesophagus and oesophagogastric junction (Group A: Stage I/II, 32; Group B: Stage III/IV, 16) underwent intraluminal Iridium-192 high dose-rate afterloading therapy (5-7 Gy/session, total dose: 5-21 Gy, mean: 12.4 Gy) and external beam irradiation (Karnofsky > or = 80% 50-60 Gy/2 Gy per day; Karnofsky 60-79%: 30 Gy/3 Gy per day). Durable satisfactory palliation (intake of at least semi-solid food) was demonstrated in 96% of patients. The mean survival for group A was 19.1 months and that for group B, 6.9 months, with a 12-month survival rate of 66% (group A) and 0% (group B) (P < 0.001). Local tumour response and complication rate were significantly dose-related with a predicted response rate of 70.5%, and a complication rate of 50% at ERD 129.3 Gy.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Brachytherapy - adverse effects
- Dose-Response Relationship, Radiation -
- Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophageal Neoplasms - radiotherapy Esophageal Neoplasms - surgery
- Female -
- Humans -
- Iridium Radioisotopes - diagnostic use
- Male -
- Middle Aged -
- Palliative Care -
- Radiotherapy Dosage -
- Survival Rate -